BTIG initiated coverage of Rapport Therapeutics (RAPP) with a Buy rating and $47 price target Rapport Therapeutics is a clinical-stage biotechnology company developing small molecule medications for neurological and psychiatric conditions, the analyst tells investors in a research note. BTIG has a high degree of confidence that the Phase 3 registrational focal epilepsy trials for RAP-219 will be successful and that the drug will receive approval.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Buy Rating for Rapport Therapeutics: Promising RAP-219 Results and Strong Financial Position
- Rapport Therapeutics price target raised to $80 from $77 at Citizens JMP
- Rapport Therapeutics Reports Q3 2025 Financial Results
- Promising Phase II Results and Strong Financial Position Drive Buy Rating for Rapport Therapeutics
- Rapport Therapeutics reports Q3 EPS (71c), consensus (73c)